Join the Oncology Voice Network. Join for Free
MSL Burnout...The Struggle is Real
MSL burnout stress management Medical Science Liaisons post-COVID challenges supportive teams

MSL Burnout...The Struggle is Real


Share This Article


Summary

In this episode, Jennifer Mohawk joins to discuss the prevalent issue of burnout among Medical Science Liaisons. She shares her insights on the common stressors, including overachievement and post-COVID challenges, that contribute to burnout in the MSL field. Jennifer addresses the impact of travel stress and the pressure of metrics, emphasizing the importance of recognizing early warning signs. She provides effective strategies for managing stress, such as midday movement and aligning personal and organizational values. The episode concludes with Jennifer's advice on building supportive, diverse teams and her final words of wisdom for MSLs.

My guest this week is Jennifer Mohawk, Senior Director, Medical Affairs with Apogee Therapeutics who discusses MSL burnout and how to handle the stress of the job.

Jen shares….

👉 What is MSL Burnout?
👉 How to pick up the warning signs
👉 What Managers can do to help with burnout
👉 What are ways to minimize and cope with the stress of the job
👉 What habits should be adopted for MSL sanity

Click for Source
MSL burnout, stress management, Medical Science Liaisons, post-COVID challenges, supportive teams

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN